Jia Jenny Liu, Conjoint Associate Professor at UNSW, Translational Lead at The Kinghorn Cancer Centre, and ESMO Leadership Development Programme Participant, shared on LinkedIn:
“What makes a cancer ‘immunotherapy sensitive’?
This question has suddenly become very real in Australia.
With two broad tumour-agnostic immunotherapy pathways now available, we have an amazing opportunity to expand access to immunotherapy across cancer types. But it also creates a real-world challenge. How do we actually decide which tumours are sufficiently ‘IO sensitive’ to treat?
Our new commissioned review in eClinicalMedicine – The Lancet Discovery Science is now published:
Tumour agnostic immunotherapy: aligning biological rationale, biomarker precision, and real-world implementation
We argue that IO sensitivity can’t always be defined by a single biomarker.
MSI-H/dMMR is probably the clearest example of a conserved immune-sensitive state. Beyond this, things get much greyer. TMB, POLE/POLD1, PD-L1, tumour lineage, the immune microenvironment, prior therapy and the clinical context can all matter.
So as tumour-agnostic access expands, access still requires interpretation.
We created a practical framework for how we think about these patients in the clinic, including where the evidence is strong, where it is context-dependent, and where we are still in a genuine clinical grey zone.
Really enjoyed putting this together with Juliana Rodrigues Beal, Niamh Coleman, James Lynam, and Vivek Subbiah, MD.”
Title: Tumour-agnostic immunotherapy: aligning biological rationale, biomarker precision, and real-world implementation
Authors: Jia Liu, Juliana Beale, Niamh Coleman, James Lynam, Vivek Subbiah
Read the Full Article
Other articles featuring Jia Jenny Liu on OncoDaily.